NANOVIRICIDES, INC.

Listed Company

NNVCCIK 0001379006NYSENon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Jun 30

Period

FY 2025

Revenue

—

Net Income

$-9.50M

Total Assets

$8.82M

Equity

$7.52M

Shares Out

21.59M

Op. Cash Flow

$-8.50M

Business

NanoViricides, Inc. is a clinical‑stage biopharmaceutical company developing antiviral therapeutics using its nanoviricides™ platform to design host‑mimetic nanomachine drugs that bind, engulf and dismantle virus particles. Its product candidates include NV‑387 (oral syrup, oral gummies, injectable and inhalation formulations), NV‑HHV‑1 (topical skin cream) and other modality‑based candidates such as NV‑HIV‑1 and replication‑encapsulated variants. Key programs are organized by modality and indication (broad‑spectrum Modality 1, HerpeCide™ Modality 2, HIVCide™ and Modality 3/4 pipelines) alongside in‑house cGMP‑capable manufacturing and analytical operations. The company advances candidates via global clinical trials, regulatory filings and licensing/collaboration distribution channels.

Summary from filing dated 2025-09-29

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Research and development	6	5	6	6	6
General and administrative	4	3	3	2	3
Total operating expenses	10	9	9	8	9
LOSS FROM OPERATIONS	−10	−9	−9	−8	−9
Interest income	124,828	271,773	355,833	11,859	9,348
Interest expense	−149	−49,808	−938	—	—
Other income (expense), net	124,679	221,965	354,895	6,736	−78,083
NET LOSS	−10	−8	−9	−8	−9
Net loss per common share- basic	−0.63	−0.7	−0.74	−0.7	−0.81
Net loss per common share- diluted	−0.63	−0.7	−0.74	−0.7	−0.81
Weighted average common shares - basic	15	12	12	12	11
Weighted average common shares - diluted	15	12	12	12	11

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Cash and cash equivalents	2	5	8	14	21
Prepaid expenses	112,146	172,742	295,486	350,021	307,102
Total current assets	2	5	8	14	21
Property and equipment, net	7	8	8	9	9
Intangible assets, net	317,039	325,308	333,578	341,848	350,118
Service agreements	2,445	14,562	14,361	38,925	0
Total assets	9	13	17	23	30
Accrued expenses	26,000	262,467	143,760	45,692	24,285
Total current liabilities	1	1	534,250	412,837	351,146
COMMITMENTS AND CONTINGENCIES (NOTE 11)	—	—	—	—	—
Common stock, $0.00001 par value; 150,000,000 shares authorized, 16,606,832 and 13,144,055 shares issued and outstanding at June 30, 2025 and 2024, respectively. (Note 8)	166	131	117	116	11,515
Additional paid-in capital	156	151	146	146	144
Accumulated deficit	−149	−139	−131	−122	−114
Total stockholders' equity	8	11	15	23	30
Total liabilities and stockholders' equity	9	13	17	23	30

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Net loss	−9	−8	−9	−8	−9
Preferred shares issued as compensation	60,722	43,245	56,357	135,400	226,306
Common shares issued as compensation and for services	162,625	178,940	157,822	203,018	179,288
Warrants granted to Scientific Advisory Board	679	563	1,012	4,215	6,103
Depreciation	735,536	750,744	739,259	715,055	696,268
Amortization	8,269	8,270	8,270	8,270	8,270
Prepaid expenses	60,596	122,744	54,535	191,279	205,436
Other assets	12,117	−201	28,079	−38,925	10,158
Accounts payable	82,824	219,213	99,096	−142,056	−180,711
Accounts payable - related parties	101,417	486,605	19,037	182,858	−530,041
Accrued expenses	−236,498	168,516	98,068	21,407	−44,953
NET CASH USED IN OPERATING ACTIVITIES	−9	−6	−6	−6	−8
Purchase of property and equipment	−56,964	−156,560	−151,712	−324,348	−238,765
NET CASH USED IN INVESTING ACTIVITIES	−56,964	−156,560	−151,712	−324,348	—
Net proceeds from sale of common stock	5	3	—	0	17
NET CASH PROVIDED BY FINANCING ACTIVITIES	5	3	−94,788	−234,716	15
NET CHANGE IN CASH AND CASH EQUIVALENTS	−3	−3	−6	−6	7
Interest paid	149	0	938	5,123	4,858
Fair value od Series A Preferred shares issued upon conversion of related party convertible promissory note	—	2	—	—	—
Forgiveness of interest on related party debt	—	49,808	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro